TENAX THERAPEUTICS, INC.

TENX

Explore Our Financial Data > Companies > TENAX THERAPEUTICS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
TENX
CIK0000034956
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, NC, 27517
Website tenaxthera.com
Phone919-855-2100
CEOChristopher T. Giordano
Employees9

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$0.00
Pre-Tax Income$-17.60 million
Net Income$-17.60 million
Net Income to Common$-17.60 million
EPS$-1.15
View All
Balance Sheet
Cash$99.37 million
Assets$102.81 million
Liabilities$6.60 million
Common Equity$96.21 million
Liabilities & Equity$102.81 million
View All
Cash Flow Statement
Net Income$-17.60 million
Cash From Operating Activities$-25.91 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$26.97 million
Change in Cash$1.06 million
View All
Calculations
NOPAT$0.00
EBITDA$0.00
Price to EarningsN/A
Price to Book$0.72
ROEN/A
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Tenax Therapeutics to Participate in Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences: 8th Annual Evercore Healthcare ConferenceFormat: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical

Article Link

Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Article Link

Tenax Therapeutics: Q3 Earnings Snapshot

CHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Wednesday reported a loss of $15.8 million in its third quarter. The Chapel Hill, North Carolina-based company said it had a loss of 40 cents per share.

Article Link

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clin

Article Link

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will host a conference call and webcast on Thursday, November 13, 2025, at 4:30 p.m. ET. Members of the management team will be joined by the below recognized key opinion leaders in cardiovascular medicine to disc

Article Link